News

For the fourth quarter, total revenue from continuing operations increased 6% to a record $37.1 million compared to $34.9 million for the fourth quarter of 2007. RA sales

According to the company, geneX is a synthetic bone graft material with a unique bi-phasic composition manufactured through a proprietary process that confers the product with a reproducible

According to CytoCore, the SoftPAP cervical cell collector offers quicker, more accurate specimen collection with minimal possibility of user error. It is designed to consistently sample the entire

According to Etex, Beta-bsm and Gamma-bsm are next generation bone substitute materials based on the company’s nanocrystalline calcium phosphate technology. This hard-setting nanocrystalline technology provides the optimal osteoconductive

Under the agreement, GTC will establish the appropriate cell lines and demonstrate production over the next 12 months. JCOM has the option for exclusive marketing rights in Asia.

The Phase I study will evaluate the safety, tolerability and pharmacokinetic profile of GTx-758 using a single ascending dose, double-blind, placebo-controlled design in healthy male volunteers. Preclinical in

The approval follows a positive opinion adopted by the Committee for Medicinal Products for Human Use of the European Medicines Agency in December 2008. Daiichi Sankyo Company and

Additionally, Abbott announced an agreement to open a new nutrition science research and development center in Singapore, where its scientists will focus on clinical trials and development of

The Phase II trial is an active (enoxaparin)-controlled, dose-escalating, multicenter, prospective, randomized, open-label trial evaluating TB-402 for the prophylaxis of deep vein thrombosis (DVT) after knee surgery. The